Axa
CHRS icon

Axa’s Coherus Oncology CHRS Stock Holding History

Axa’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-142,400
Closed -$533K – 1078
2023
Q3 		$533K Hold
142,400
– – ﹤0.01% 930
2023
Q2 		$608K Buy
+142,400
New +$840K ﹤0.01% 923
2019
Q1 		– Sell
-58,779
Closed -$532K – 1320
2018
Q4 		$532K Sell
58,779
-350,104
-86% -$4.05M ﹤0.01% 1077
2018
Q3 		$6.75M Hold
408,883
– – 0.02% 587
2018
Q2 		$5.72M Buy
408,883
+5,203
+1% +$74.5K 0.02% 620
2018
Q1 		$4.46M Sell
403,680
-3,974
-1% -$43.5K 0.02% 682
2017
Q4 		$3.59M Sell
407,654
-406
-0.1% -$4.35K 0.01% 733
2017
Q3 		$5.45M Sell
408,060
-5,668
-1% -$75K 0.02% 605
2017
Q2 		$5.94M Buy
413,728
+44,976
+12% +$865K 0.03% 563
2017
Q1 		$7.8M Buy
368,752
+59,019
+19% +$1.45M 0.04% 485
2016
Q4 		$8.72M Buy
309,733
+5,911
+2% +$165K 0.04% 441
2016
Q3 		$8.14M Sell
303,822
-103,770
-25% -$2.83M 0.04% 461
2016
Q2 		$6.88M Sell
407,592
-41,197
-9% -$773K 0.03% 494
2016
Q1 		$9.53M Buy
+448,789
New +$7.35M 0.04% 401

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's CHRS Position: Q4 2023 in Review

Axa sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 142,400 shares — an estimated $533K sold.

Axa first reported a position in CHRS in Q1 2016 and held it in 14 quarters. The position peaked at $9.53M in Q1 2016. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Axa reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Axa sold 142,400 Coherus Oncology shares in Q4 2023, an estimated $533K.
  • Axa first reported a position in Coherus Oncology in Q1 2016 and held it in 14 quarters.
  • Axa's Coherus Oncology position peaked at $9.53M in Q1 2016.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Axa's 13F filing for Q4 2023, filed 14 Feb 2024.